MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers
The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a complex, synthetic microbial consortium with the goal of expanding the number of cancer patients who respond to immunotherapy....
Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of the gut microbiome as a targetable biomarker to improve responses to immunotherapy were presented today at the 2022 American Society for Clinical Oncology...
Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Therapy With IGEN-0206
A national, multicenter, blind, randomized study of three groups, designed to evaluate the impact on the quality of life of IGEN-0206 (IGEN-0206 is a nutritional product, a food) with nutritional support + standard treatment versus nutritional support + standard...
